Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Unknown 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Head & Neck 2Gastrointestinal 2Breast 2Other solid neoplasm 1Gynecologic 1Genitourinary 1Dermatologic 1

Conditions

Breast Neoplasms 8Triple Negative Breast Neoplasms 6Head and Neck Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Melanoma 5Urinary Bladder Neoplasms 4Ovarian Neoplasms 4Neoplasms 4Stomach Neoplasms 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Colorectal Neoplasms 3Carcinoma, Merkel Cell 3Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Prostatic Neoplasms 2Gastrointestinal Neoplasms 2Colonic Neoplasms 2Carcinoma, Renal Cell 2Uveal Melanoma 1Uterine Neoplasms 1Thyroid Neoplasms 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Sarcoma 1Recurrence 1Pathologic Complete Response 1Mesothelioma, Malignant 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1

Interventions

Surveys and Questionnaires 7Nivolumab 5atezolizumab 3Radiosurgery 3Blood Specimen Collection 3pertuzumab 2pembrolizumab 2pazopanib 2cemiplimab 2amminedichloro(2-methylpyridine)platinum(II) 2alectinib 2Magnetic Resonance Spectroscopy 2Interviews as Topic 2Drug Therapy 2Capecitabine 2tepotinib 1talazoparib 1selpercatinib 1pralsetinib 1ponatinib 1pemigatinib 1palbociclib 1motexafin gadolinium 1montanide ISA 51 1mannide monooleate 1itacitinib 1ipatasertib 1fludarabine 1entrectinib 1durvalumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Gastrointestinal Neoplasms × cemiplimab × Breast × Clear all
NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Jules Bordet Institute

Phase 2 Unknown
441 enrolled
BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT04460456 2022-06-30

A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors

Silverback Therapeutics

Phase 1 Unknown
58 enrolled
BreastGastrointestinalGynecologicHead & NeckThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡